Baclofen, a muscle relaxant approved for treating spasticity, has shown consistent anxiolytic effects across several small clinical trials, though it remains an off-label option for anxiety disorders. Originally designed as a brain-penetrant form of the neurotransmitter GABA, baclofen works by activating GABA-B receptors throughout the brain, including in regions that govern fear and emotional arousal. The evidence is preliminary and scattered across different patient populations, but the signal is real enough that researchers and some clinicians take it seriously.
How Baclofen Got Here
Baclofen was synthesized in the 1960s with a specific goal: to create a version of GABA that could actually cross from the bloodstream into the brain, something GABA itself cannot do efficiently. The original target was epilepsy, but that did not pan out. Instead, researchers noticed that baclofen was a powerful muscle relaxant, and it was approved for spasticity, the painful muscle stiffness that accompanies conditions like multiple sclerosis and spinal cord injuries.1ACS Chemical Neuroscience. Classics in Chemical Neuroscience: Baclofen Its anxiolytic properties were observed along the way, mostly as a secondary finding in trials designed to study something else. That pattern continues today: much of what we know about baclofen and anxiety comes from research focused on alcohol dependence, PTSD, or schizophrenia, where anxiety was measured as an outcome but was not the primary question.
What Baclofen Does in the Brain
Baclofen is a selective GABA-B receptor agonist, meaning it activates one of the two main receptor types for GABA, the brain’s primary inhibitory neurotransmitter.2PubMed Central. A Review of the Potential Mechanisms of Action of Baclofen in Alcohol Use Disorder GABA-B receptors are distinct from the GABA-A receptors targeted by benzodiazepines and alcohol, which matters for understanding both its effects and its safety profile. When baclofen activates GABA-B receptors, it generally slows neural activity, reducing the excitability of neurons in circuits involved in stress, reward, and emotional processing.
The most anxiety-relevant research involves the central amygdala, a brain region critical for generating fear responses. In laboratory recordings, baclofen dramatically reduced excitatory signaling flowing into the central amygdala. Stimulation from the lateral amygdala saw signal strength drop by roughly 75%, while inputs from another pathway were cut by about 57%.3PubMed Central. Baclofen acts in the central amygdala to reduce synaptic transmission and impair context fear conditioning This was not just dampening excitatory signals; baclofen also reduced inhibitory transmission, essentially quieting the entire circuit. The functional result in animal experiments was a clear impairment in conditioned fear, the learned association between a context and a threatening event. That kind of learned fear is central to how anxiety disorders maintain themselves.
Brain imaging in humans tells a complementary story. In people with alcohol dependence given 75 mg/day of baclofen, activity in the insula, a region involved in processing internal bodily signals and anticipatory anxiety, was significantly reduced when participants were exposed to threatening cues, compared to placebo.4PubMed. High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals The insula is thought to play a role in the physical sense of dread, the gut-level feeling that something bad is about to happen. Turning down that signal could explain why patients on baclofen often report feeling less anxious even when their circumstances have not changed.
Clinical Evidence for Anxiety Reduction
The clinical data on baclofen and anxiety comes from several different patient groups, and no large randomized trial has been conducted specifically in people with generalized anxiety disorder or panic disorder. What exists is a collection of smaller studies, each pointing in the same direction.
Alcohol Dependence
A randomized, double-blind trial in people with alcohol dependence found that those assigned to baclofen had lower state anxiety scores on average compared to the placebo group. Estimated mean state anxiety was about 27.5 in the baclofen group versus 32.2 in the placebo group, a statistically significant difference.5PubMed Central. Efficacy and Safety of Baclofen for Alcohol Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial This is meaningful because anxiety is both a driver of relapse and a common co-occurring condition in people with alcohol problems. It also suggests the anxiolytic effect is not simply a result of drinking less.
Post-Traumatic Stress Disorder
Two studies have examined baclofen in PTSD, both small but both positive. In an open-label trial of 14 patients (11 completers), eight weeks of baclofen reduced total scores on the Clinician-Administered PTSD Scale from about 83 to about 64. The avoidance and hyperarousal symptom clusters improved significantly, though re-experiencing symptoms did not change.6PubMed. Baclofen treatment for chronic posttraumatic stress disorder A separate randomized trial tested baclofen added to citalopram (an SSRI) and found significantly greater improvement in PTSD severity, anxiety, and depression compared to citalopram plus placebo.7PubMed. Baclofen add-on to citalopram in treatment of posttraumatic stress disorder The pattern of improvement in avoidance and hyperarousal, the “always on edge” symptoms, fits neatly with the amygdala and insula findings described earlier.
Schizophrenia
A double-blind, placebo-controlled trial in patients with schizophrenia used baclofen as an add-on to standard antipsychotic treatment. Anxiety and depression scores in the baclofen group decreased from the second week onward, while the placebo group’s scores stayed flat or worsened. By week four, the difference between groups was large and statistically significant.8Middle East Journal of Rehabilitation and Health Studies. The Therapeutic Effects of Baclofen as Adjunctive Therapy on Positive and Negative Symptoms of Schizophrenia: A Double-Blind Randomized Placebo-Controlled Clinical Trial – Section: Anxiety and Depression Symptoms This is notable because many standard anxiolytics are tricky to use in schizophrenia: benzodiazepines carry abuse risk and can worsen cognitive issues, while some antidepressants interact poorly with antipsychotics.
How Baclofen Compares to Benzodiazepines
The comparison that comes up most often is with benzodiazepines, the class of drugs like lorazepam, diazepam, and alprazolam that dominate anxiety treatment. Both drug classes enhance GABA signaling, but they do so through entirely different receptor subtypes: benzodiazepines work on GABA-A receptors, baclofen on GABA-B. This distinction has practical consequences.
Benzodiazepines carry well-documented risks of dependence, abuse, memory impairment, and dangerous respiratory depression, especially in people with liver problems. A study comparing baclofen and lorazepam in alcohol withdrawal noted that baclofen avoids these issues: it has low abuse potential, does not appear to produce craving, and does not cause withdrawal symptoms of its own kind when discontinued in patients who were on regular (non-abrupt) treatment courses.9PubMed Central. Comparative efficacy of baclofen and lorazepam in the treatment of alcohol withdrawal syndrome For people with a history of substance use, this is a significant advantage.
The trade-off is that baclofen is not as fast-acting or as reliably powerful for acute anxiety as a benzodiazepine. It takes time to titrate to an effective dose, and the anxiolytic effect in most studies is moderate rather than dramatic. It also has not been tested head-to-head against benzodiazepines or SSRIs in a proper anxiety disorder trial, so direct comparisons remain speculative.
Side Effects at Therapeutic Doses
The most common side effects of oral baclofen are sedation, excessive muscle weakness, dizziness, and psychological disturbances. The reported incidence ranges from about 10% to 75% depending on the study and population, but most side effects are dose-related and either transient or reversible when the dose is adjusted.10PubMed. A benefit-risk assessment of baclofen in severe spinal spasticity Sedation and drowsiness are the complaints you hear about most frequently, and they tend to be worst during the first few days on a new dose level, then ease as the body adjusts.
Psychological side effects deserve attention. Some patients experience confusion, euphoria, or depression, particularly at higher doses. In the French prescribing survey that looked at high-dose baclofen use for alcohol dependence (mean doses around 110 mg/day, well above the spasticity range), over 60% of prescribers considered high-dose baclofen less safe than approved drugs, even as a majority also considered it more effective.11PubMed Central. Off-label baclofen prescribing practices among French alcohol specialists: results of a national online survey That tension, where clinicians acknowledge both greater efficacy and greater safety concerns, captures baclofen’s current status well.
Why Stopping Matters
One area where baclofen’s safety profile is less forgiving than often assumed is withdrawal. Abruptly stopping baclofen, especially after prolonged use, can trigger delirium.12PubMed. Delirium associated with baclofen withdrawal: a review of common presentations and management strategies This is not the same as the anxiety rebound you might get from stopping a benzodiazepine. Baclofen withdrawal delirium can look like a medical emergency, with confusion, agitation, and autonomic instability. The risk appears to be greater in people who have been on baclofen for a long time. The practical takeaway is simple: never stop baclofen abruptly. Doses should always be tapered gradually, and both patients and their doctors need to know this before starting treatment.
The withdrawal risk does not mean baclofen is addictive in the way benzodiazepines can be. People do not typically crave baclofen or escalate doses for euphoria. The problem is neurological: the brain adapts to continuous GABA-B activation, and removing that input suddenly creates a rebound excitatory state. It is a physiological dependence issue, not a behavioral addiction issue, but the practical danger is real either way.
Overdose and Toxicity
Baclofen overdose is a genuine medical concern, particularly because of how alarming the symptoms can look. Overdose can cause deep coma with loss of brainstem reflexes, a presentation so severe it can mimic brain death.13PubMed. Coma mimicking brain death following baclofen overdose Other symptoms include respiratory depression, seizures, extremely slow heart rate, low blood pressure, and loss of muscle tone. Symptoms typically appear within two to six hours of ingestion.14J Pediatr Emerg Intensive Care Med. Recognizing and Managing Life-threatening Toxicity in Pediatric Baclofen Poisoning: A Case Report – Section: Discussion
The critical point, and a genuinely reassuring one, is that patients with even severe baclofen overdose often recover fully within about 72 hours if the overdose is recognized and managed with appropriate supportive care.15PubMed Central. Baclofen overdose mimicking anoxic encephalopathy: a case report and review of the literature There is no specific antidote; treatment is supportive, focused on maintaining breathing and cardiovascular stability. The danger lies in misdiagnosis: if emergency physicians mistake baclofen coma for irreversible brain injury, they may withdraw support prematurely. Awareness of this presentation is important for anyone taking baclofen and for their families.
How the Body Handles Baclofen
Understanding baclofen’s pharmacokinetics helps explain both its limitations and some of its safety quirks. The drug is well absorbed from the gut, with oral bioavailability above 80-90%.16PubMed. Intrathecal baclofen. Experimental and pharmacokinetic studies However, despite being designed to cross the blood-brain barrier better than GABA itself, baclofen still does not penetrate the brain especially well. This is actually a significant limitation: the failure of oral baclofen to produce adequate spasticity relief in some patients is attributed to poor brain penetration, and the same issue may limit its anxiolytic ceiling. This is why intrathecal (spinal) baclofen pumps exist for severe spasticity, though they are not used for anxiety.
About 65% of an oral dose is excreted unchanged by the kidneys, with renal clearance roughly matching creatinine clearance.17PubMed. Pharmacokinetics of baclofen in spastic patients receiving multiple oral doses This has a direct clinical implication: people with impaired kidney function accumulate baclofen and can develop toxicity at standard doses. If you have kidney disease and are considering baclofen, your doctor needs to adjust the dose downward and monitor you more closely. This kidney-dependent clearance also means that baclofen has relatively predictable pharmacokinetics in people with normal kidney function, and drug-drug interactions are less of a concern than with medications processed by the liver.
The Off-Label Reality
Baclofen is not approved by the FDA or any major regulatory agency for the treatment of anxiety disorders. Its approved indication remains spasticity. Everything discussed in this article about anxiety is off-label use, which means prescribers are relying on clinical judgment and published evidence rather than regulatory-level proof of efficacy. This is neither unusual nor inherently inappropriate in psychiatry, where off-label prescribing is common for many conditions, but it does mean that insurance coverage can be inconsistent and that the evidence base is thinner than what you would find for an approved indication.
In practice, baclofen for anxiety is most commonly considered in specific situations rather than as a first-line treatment. Patients with co-occurring alcohol problems are the most studied population, and the overlap between alcohol dependence and anxiety makes baclofen an appealing dual-purpose option. People who have not responded well to SSRIs or who cannot tolerate benzodiazepines due to addiction history are another group where clinicians may reach for baclofen. The typical starting dose is low, often 5 mg two or three times daily, with gradual increases. Most of the anxiety-relevant trials used doses in the range of 30 to 80 mg/day, though doses for alcohol dependence have gone much higher.
Gaps in What We Know
The largest gap in the evidence is the absence of any randomized controlled trial designed specifically to test baclofen as a treatment for a primary anxiety disorder, such as generalized anxiety disorder, social anxiety disorder, or panic disorder, in people without co-occurring substance use. Every positive finding comes from populations where anxiety was a secondary concern. It is plausible that baclofen would help in these broader populations, given the consistency of the signal and the clear mechanistic rationale, but plausible is not the same as proven.
Another open question is dose-response. In the brain imaging study on anticipatory anxiety, the effect was seen at 75 mg/day but not at 30 mg/day, hinting that higher doses may be needed for meaningful anxiolytic effects.4PubMed. High-dose baclofen attenuates insula activation during anticipatory anxiety in treatment-seeking alcohol dependant individuals But higher doses bring more side effects, especially sedation and the psychological disturbances mentioned earlier. Finding the sweet spot, enough brain exposure to reduce anxiety without unacceptable sedation, remains a challenge without formal dose-finding studies.
There is also the question of long-term use. Most trials lasted eight weeks or less. Whether baclofen maintains its anxiolytic effect over months or years, whether tolerance develops, and what the safest approach is for people who benefit and want to continue, are questions that current data cannot answer with any confidence. The withdrawal risk makes this particularly relevant: a drug you might need to take indefinitely but cannot stop abruptly requires a higher standard of long-term safety data than currently exists.
Who Should Think Twice
Certain populations face elevated risks with baclofen. People with kidney impairment are at the top of that list, since the drug accumulates when renal clearance is reduced. Elderly patients, who often have reduced kidney function even when blood tests look relatively normal, may need lower doses and closer monitoring. Anyone with a history of seizures should be cautious, since baclofen withdrawal can provoke seizures, and even overdose can trigger them. People who live alone or who might struggle to maintain a consistent medication schedule face added risk from the withdrawal issue: a missed refill or a few skipped doses in someone on a stable high dose could precipitate delirium.
Pregnancy is another consideration with limited data. Baclofen crosses the placenta, and animal studies have shown adverse effects at high doses, so most clinicians avoid prescribing it during pregnancy unless the benefits clearly outweigh the risks for the specific patient. If you are pregnant or planning to become pregnant and currently taking baclofen for any reason, that conversation with your prescriber should happen before you make any changes on your own, given the withdrawal risks of abrupt discontinuation.